TITLE

PEANUT LECTIN CAUSES COLONIC PROLIFERATION VIA INTERACTION WITH CD44V6 AND SUBSEQUENT C-MET AND MAP KINASE PHOSPHORYLATION--A POSSIBLE MECHANISM FOR BACTERIA INDUCED COLONIC PROLIFERATION

PUB. DATE
April 2004
SOURCE
Gut;Apr2004 Supplement 3, Vol. 53, pA120
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
CD44 splice variants and the receptor tyrosine kinase c-Met have independently been identified as tumour metastasis associated proteins and are predictors of tumour invasion and poor prognosis in colon cancer. The presence of CD44V6 splice variants correlates with colonic crypt proliferation and has recently been shown to be essential for c-Met activation by its ligand HGF/SF. This article focuses on an experiment that shows by co-immunoprecipitation that CD44V6 and c-Met physically associate with each other in HT29 colon cancer cells, and that PNA induces phosphorylation of c-Met and subsequently MAP kinase.
ACCESSION #
13219283

 

Related Articles

  • Activating mutation in MET oncogene in familial colorectal cancer.  // BMC Cancer;2011, Vol. 11 Issue 1, p424 

    The article presents a study that examines the proto-oncogene and tyrosine kinase receptor, MET, genetic mutation in familial colorectal cancer (CRC). A germline non-synonymous change in the MET proto-oncogene at amino acid position affected with CRC was examined. It is given that threonine at...

  • Phase I trial of interleukin-2 and high-dose arginine butyrate in metastatic colorectal cancer. Douillard, J. Y.; Bennouna, J.; Vavasseur, F.; Deporte-Fety, R.; Thomare, P.; Giacalone, F.; Meflah, K. // Cancer Immunology, Immunotherapy;Mar2000, Vol. 49 Issue 1, p56 

    Introduction: Interleukin-2 (IL-2) and sodium butyrate allow rats to be cured of peritoneal carcinomatosis from colon cancer. We performed a phase I trial of IL-2 and high-dose arginine butyrate (ArgB) in patients with advanced metastatic colorectal cancer. Patients and methods: From April to...

  • EphB—ephrin-B interactions suppress colorectal cancer progression by compartmentalizing tumor cells. Cortina, Carme; Palomo-Ponce, Sergio; Iglesias, Mar; Fernández-Masip, Juan Luis; Vivancos, Ana; Whissell, Gavin; Humà, Mireia; Peiró, Nerea; Gallego, Lourdes; Jonkheer, Suzanne; Davy, Alice; Lloreta, Josep; Sancho, Elena; Batlle, Eduard // Nature Genetics;Nov2007, Vol. 39 Issue 11, p1376 

    The genes encoding tyrosine kinase receptors EphB2 and EphB3 are β-catenin and Tcf4 target genes in colorectal cancer (CRC) and in normal intestinal cells. In the intestinal epithelium, EphB signaling controls the positioning of cell types along the crypt-villus axis. In CRC, EphB activity...

  • Missense polymorphisms of PTPRJ and PTPN13 genes affect susceptibility to a variety of human cancers. Mita, Yuichiro; Yasuda, Yukiko; Sakai, Akiko; Yamamoto, Hiromasa; Toyooka, Shinichi; Gunduz, Mehmet; Tanabe, Shunsuke; Naomoto, Yoshio; Ouchida, Mamoru; Shimizu, Kenji // Journal of Cancer Research & Clinical Oncology;Feb2010, Vol. 136 Issue 2, p249 

    We investigated the association between incidence of various cancers and four single nucleotide polymorphisms (SNPs), two each in two protein tyrosine phosphatase (PTP) genes, PTPRJ and PTPN13, by a case–control study conducted in Japan. The study samples comprised 819 cancer-free...

  • S100A7-Downregulation Inhibits Epidermal Growth Factor-Induced Signaling in Breast Cancer Cells and Blocks Osteoclast Formation. Paruchuri, Vikram; Prasad, Anil; McHugh, Kevin; Bhat, Hari K.; Polyak, Kornelia; Ganju, Ramesh K. // PLoS ONE;2008, Vol. 3 Issue 3, p1 

    S100A7 is a small calcium binding protein, which has been shown to be differentially expressed in psoriatic skin lesions, as well as in squamous cell tumors of the skin, lung and breast. Although its expression has been correlated to HER+ high-grade tumors and to a high risk of progression, the...

  • N-Terminal c-Fos tyrosine phosphorylation regulates c-Fos/ER association and c-Fos-dependent phospholipid synthesis activation. Portal, M. M.; Ferrero, G. O.; Caputto, B. L. // Oncogene;5/24/2007, Vol. 26 Issue 24, p3551 

    c-Fos dephosphorylated on tyrosine (c-Fos), a component of the activator protein-1 (AP-1) family of transcription factors, is expressed at very low levels in resting cells. However, its expression is rapidly upregulated in cells undergoing G0 to S phase transition leading to AP-1-dependent gene...

  • Regulation of the Wnt signalling component PAR1A by the Peutz-Jeghers syndrome kinase LKB1. Spicer, James; Rayter, Sydonia; Young, Neville; Elliott, Richard; Ashworth, Alan; Smith, Darrin // Oncogene;7/24/2003, Vol. 22 Issue 30, p4752 

    Loss-of-function mutations in the LKB1 (STK11) serine-threonine kinase gene cause Peutz-Jeghers syndrome, which is associated with inherited susceptibility to colorectal and other cancers. No downstream targets of LKB1 kinase activity have been identified. Here we show that LKB1 can direct the...

  • Genetic Testing for a Family History of Colon Cancer? Maybe, Maybe Not. Roy, H. K.; Thompson, Jon S. // American Journal of Gastroenterology;Feb1998, Vol. 93 Issue 2, p258 

    Discusses research being done on familial colorectal cancer in Ashkenazim due to a hypermutable tract in adenomatous polyposis coli (APC). Reference to a study by S. J. Laken et al.; Cause of amino acid substitution; Knowledge of the APC status.

  • Population pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors. Feng Guo; Letrent, Stephen P.; Sharma, Amarnath // Cancer Chemotherapy & Pharmacology;Dec2007, Vol. 60 Issue 6, p799 

    To develop a population pharmacokinetic (popPK) model for CP-724,714, a novel HER2 tyrosine kinase inhibitor is under development for the treatment of advanced HER2 positive cancers. Concentration-time data ( n = 484) from 30 cancer patients receiving daily oral CP-724,714 at doses of 250 mg QD,...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics